1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.

Slides:



Advertisements
Similar presentations
Preclinical Drug Development Miss Sirikan Nawapan.
Advertisements

Chronic Disease and Co-morbidity with Hearing Loss
Poster will be available at after September 10 th 2006 ABSTRACT AN2690 is a new novel antifungal being developed for the treatment of onychomycosis.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Nonclinical Pharmacology/ Toxicology Data for PROTOPIC  (Tacrolimus ointment for Atopic Dermatitis) Barbara Hill, Ph.D. Division of Dermatologic and Dental.
1 Copyright © 2005 Brooks/Cole, a division of Thomson Learning, Inc. Analysis of Categorical Data Tests for Homogeneity.
Pediatric Subcommittee of the AIDAC October 29-30, 2003 Topical Immunosuppressants Bindi M. Nikhar, M.D., FAAP Division of Dermatologic and Dental Drug.
Roberts AW et al. Proc ASH 2014;Abstract 325.
Allergy and Hypersensitivity K. J. Goodrum Types of Immune Hypersensitivity Reactions.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.
LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE
1 Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology Pediatric Advisory Committee Meeting February 15, 2005 Barbara Hill, Ph.D. Division.
Rapivab™ - peramivir injection
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Clinical Review of Protopic Safety, Potential Risk, and Efficacy Martin M. Okun, M.D., Ph.D. Lisa Mathis, M.D. Division of Dermatologic and Dental Drug.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
© 2010 Universitair Ziekenhuis Gent Population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients translated into clinical.
OCTOBER 27, 2011 GOOD MORNING! WELCOME APPLICANTS!
Gastrointestinal Review Highlights of the VIGOR Trial Lawrence Goldkind M.D.
CA-1 Preclinical Studies Philip Bentley, PhD Vice President Toxicology/Pathology Novartis Pharmaceuticals Corporation Philip Bentley, PhD Vice President.
Toujeo® and it’s Place in Therapy
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Elizabeth Gorevski Kingsbrook Jewish Medical Center Brooklyn, NY.
Drug Metabolism and Pharmacokinetics Core Goal: To provide comprehensive pharmacology support for preclinical and clinical research.
Biostatistics in Practice Peter D. Christenson Biostatistician Session 6: Case Study.
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.
Display 4-1: Therapies that Disqualified Patients as Responders  Phototherapy (PUVA, UVB)  Systemic retinoids  High potency topical corticosteroids.
EHS 507 Potential dose: the amount of chemical that is ingested or inhaled, or the amount of chemical contained in material applied to skin. Applied dose:
Atopic Dermatitis: Disease Impact and Therapy
Background Derma-Smoothe/FS ® (Fluocinolone acetonide ) Contains 0.01% fluocinolone acetonide in an oil base solution, Categorized as a low to medium potency.
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Background Conclusions low weight, CYP3A5*1 allele, low gamma glutamyl transpeptidase and low hematocrit are associated with a higher tacrolimus clearance.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Pediatric Subcommittee of the AIDAC October 29-30, Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology October 30, 2003 Barbara.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.
Disease modified Anti-rheumatic drugs ( DMARD)
CS-1 Elidel ® (pimecrolimus) Cream 1% Safety Update Feb, 2005 Thomas Hultsch, MD Senior Medical Director Novartis Pharmaceuticals Corporation Thomas Hultsch,
Alemtuzumab BLA committee CD52 Expression Leukocytes B- lymphocytes T- lymphocytes Monocytes Macrophages Thymocytes Granulocytes (
1 11/8/00 Efficacy and Safety of Tacrolimus Ointment Ira D. Lawrence, M.D., F.A.C.P. Senior Vice President Research and Development Fujisawa Healthcare,
Foundation Knowledge and Skills
Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Accutane ® Use and Epidemiology John E. La Flore, MD, MSPH Vice President, Drug Safety & Risk Management Hoffmann-La Roche Inc.
The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Eucrisa™ - Crisaborole
Drug Discovery &Development
Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development Thomas Dumortier, Martin Fink, Ovidiu.
Emerging Mechanisms in Glucose Metabolism
Management of perioperative hypertension
Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang,
Pharmacologically Antagonizing the CXCR4-CXCL12 Chemokine Pathway with AMD3100 Inhibits Sunlight-Induced Skin Cancer  Seri N.E. Sarchio, Richard A. Scolyer,
Longitudinal Analysis Beyond effect size
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.
Lawrence F. Eichenfield, MD, Lisa Beck, MD 
Therapeutic Drug Monitoring chapter 1 part 1
Thomas Schwarz  Journal of Investigative Dermatology 
Yang Liu, Anne Chain, Rebecca Wrishko,
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Generalized pruritus Dermatologic (arising from diseases of the skin)
Akane Tanaka, Susumu Muto, Kyungsook Jung, Akiko Itai, Hiroshi Matsuda 
Methotrexate and azathioprine in severe atopic dermatitis: A 5-year follow up study of a randomised controlled trial L.A.A. Gerbens, S.A.S Hamann, M.W.D.
Presentation transcript:

1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.

2 Pharmacology of Tacrolimus Ointment Topical macrolide (non-steroidal) immunomodulator Topical macrolide (non-steroidal) immunomodulator Inhibits calcineurin phosphatase activity in T-lymphocytes leading to decreased synthesis of cytokines associated with atopic dermatitis Inhibits calcineurin phosphatase activity in T-lymphocytes leading to decreased synthesis of cytokines associated with atopic dermatitis Decreases inflammatory mediator release from skin mast cells and basophils Decreases inflammatory mediator release from skin mast cells and basophils

3 Nonclinical Studies of Tacrolimus Ointment 27 studies conducted 27 studies conducted 3 chronic studies 3 chronic studies – 104-week topical carcinogenicity in B6C3F 1 mice – 52-week photocarcinogenicity in hairless mice – 52-week topical toxicity in micropigs

4 Topical Carcinogenicity Study in Mice 104 weeks (lifetime of animal) 104 weeks (lifetime of animal) No increase in skin tumors No increase in skin tumors Mice had 89 times higher systemic tacrolimus exposure than typical atopic dermatitis patients Mice had 89 times higher systemic tacrolimus exposure than typical atopic dermatitis patients Increased incidence of non- cutaneous lymphomas in 0.1% tacrolimus group Increased incidence of non- cutaneous lymphomas in 0.1% tacrolimus group

5 Photocarcinogenicity Study in Hairless Mice 52 week study with controlled UVR exposure 52 week study with controlled UVR exposure All animals develop skin tumors All animals develop skin tumors Median time to onset of tumor is the primary endpoint Median time to onset of tumor is the primary endpoint

6 Photocarcinogencity in Hairless Mice (combined male & female) MTO: Median Tumor Onset: mortality adjusted time at which one-half of the group has one or more tumors > 1 mm 2. Tumor Amplification Factor: relative influence of a test article on the response of skin to UVR exposure. Tacrolimus(%) MTO (Weeks) Tumor Amplification Factor UntreatedControl421.0Vehicle

7 Topical Toxicity Study in Micropigs 52 weeks 52 weeks Micropig (juvenile to adult) Micropig (juvenile to adult) Up to 3% tacrolimus ointment Up to 3% tacrolimus ointment Blood levels similar to humans Blood levels similar to humans 40% Body Surface Area treated 40% Body Surface Area treated No noteworthy topical or systemic findings No noteworthy topical or systemic findings

8 Nonclinical Studies Conclusions Tacrolimus is not a mutagen or carcinogen Tacrolimus is not a mutagen or carcinogen In a 2 year mouse study, there was no increase in skin tumors In a 2 year mouse study, there was no increase in skin tumors In mice, high skin permeability and high blood levels resulted in immunosuppression and lymphoma In mice, high skin permeability and high blood levels resulted in immunosuppression and lymphoma In a mouse model, median time to onset of photo- induced skin tumors is reduced with vehicle and active treatment In a mouse model, median time to onset of photo- induced skin tumors is reduced with vehicle and active treatment No noteworthy topical or systemic toxicity in micropigs No noteworthy topical or systemic toxicity in micropigs

9 Early Patch Testing in Humans Tacrolimus Ointment No evidence for: No evidence for: – Contact hypersensitivity – Phototoxicity – Photosensitization – Reduction of collagen synthesis in the skin

10 Pharmacokinetic Study -008 in Atopic Dermatitis Patients 0.3% tacrolimus ointment 0.3% tacrolimus ointment – Single application on days 1 and 8 – Twice daily application days 2 through 7 Protocol-defined area of application Protocol-defined area of application – Pediatric: 50 or 100 cm 2 – Adult: 100 to 5000 cm 2 Minimal systemic absorption (bioavailability < 0.5%) Minimal systemic absorption (bioavailability < 0.5%) No systemic accumulation No systemic accumulation

11 Phase III US Studies Distribution of Tacrolimus Blood Concentration 0.03% Tacrolimus Ointment (n=195)(n=25)

12 Phase II/III US Studies Blood Concentrations-Pediatric Patients (n=78) 0.03% Tacrolimus Ointment 87% 12% 1% 0%

13 Phase III US Studies Distribution of Tacrolimus Blood Concentration 0.1% Tacrolimus Ointment (n=193)(n=30)

14 Mean Blood Levels (ng/mL) 0.1% Tacrolimus Ointment Visit Week 1 Week 12 Month 6 Month 12 AdultMean N PediatricMean N2618--AdultMean N USEurope

15 Population Pharmacokinetic Analysis 462 patients in US clinical trials 462 patients in US clinical trials Average % BSA affected at baseline = 43% Average % BSA affected at baseline = 43% Estimation of “typical” exposure Estimation of “typical” exposure Nonlinear Mixed Effect Modeling (NONMEM) Nonlinear Mixed Effect Modeling (NONMEM) Steady state concentration0.25 ng/mL AUC 0-24 hours 6 nghr/mL Similar in pediatrics Similar in pediatrics

16 Hypothetical Worst Case Systemic Exposure in Atopic Dermatitis Patients European adult pharmacokinetic study European adult pharmacokinetic study – Application of 0.1% tacrolimus ointment – AUC 0-24 hours = 20 nghr/mL Model assumptions (contrary to clinical evidence) Model assumptions (contrary to clinical evidence) – lesions don’t heal – % affected BSA doesn’t decrease – quantifiable blood concentration for prolonged periods

17 Typical AD Patient Hypothetical Worst Case AD Patient Transplant Patient Transplant Patient with PTLD Mice with Lymphoma Cumulative AUC 122 days 732 1,410 55,144 79,208 65,392 Comparative AUC for Tacrolimus Blood Levels

18 Relative to AD Patients: Transplant Recipients with PTLD Mice with Lymphoma Hypothetical “Worst” Case 39x 56x 46x “Typical” Case 75x 108x 89x Relative Cumulative Systemic Exposure of Tacrolimus Based on Blood Levels

19 Clinical Pharmacology Conclusion Minimal systemic absorption Minimal systemic absorption – Most patients do not have quantifiable levels No systemic accumulation No systemic accumulation – Levels are transient Pediatric patients have a lower frequency of detectable blood levels and lower average levels than adults Pediatric patients have a lower frequency of detectable blood levels and lower average levels than adults Large safety margin in comparison to immunosuppressed transplant patients or mice Large safety margin in comparison to immunosuppressed transplant patients or mice